Oscar Health CEO's Repeated Profit Promise Highlights Fragile 2026 Turnaround

What happened

Oscar Health CEO Mark Bertolini has reiterated for the fourth consecutive quarter that 2026 will mark the company's return to profitability, as per a recent article. This promise aligns with the explicit 2026 guidance detailed in the DeepValue master report, which targets an MLR of 82.4%–83.4% and operating earnings of $250M–$450M. However, the report underscores that OSCR's FY2025 saw a sharp deterioration with an MLR of 87.4% and a $443.2M net loss, making the 2026 goals highly ambitious. Critical risks include persistent risk-adjustment payables near 20% of premium and the need for paid membership to stabilize around 3.0M entering 2Q26. Investors should remain skeptical until 1Q26 and 2Q26 results provide tangible evidence that the MLR is trending towards the target band.

Implication

The CEO's repeated assurance does not change the fundamental investment case, which hinges on Oscar delivering a 400-500 bps MLR improvement from 2025 levels. In the short term, stock volatility may be driven by sentiment shifts, but intrinsic value depends on hitting specific operational milestones. If 1Q26 and 2Q26 MLR prints approach the 82.4%–83.4% range and paid members near 3.0M, the bull case with implied value up to $20 could materialize. However, any deviation, such as MLR remaining above 85% or membership shortfalls, risks triggering the bear case with value near $9. Consequently, the DeepValue report's WAIT rating is justified, emphasizing a cautious stance until clearer signals emerge in the next 3-6 months.

Thesis delta

The new article does not introduce any material shift in the investment thesis. It merely echoes management's existing guidance, which is already factored into the DeepValue report's analysis. The core thesis remains that OSCR's valuation discounts a 2026 rebound, but proof is required from upcoming quarterly results, and investors should hold off until then.